NASDAQ: BIAF
Bioaffinity Technologies Inc Stock Forecast, Predictions & Price Target

Be the first to know when Wall Street analysts revise their BIAF stock forecasts and price targets.

Forecast return on equity

Is BIAF forecast to generate an efficient return?

Forecast return on assets

Is BIAF forecast to generate an efficient return on assets?

Company
-165.02%
Industry
10.25%
BIAF is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

BIAF earnings per share forecast

What is BIAF's earnings per share in the next 2 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$14.69
Avg 2 year Forecast
-$8.26

BIAF revenue forecast

What is BIAF's revenue in the next 2 years based on estimates from 3 analysts?

Avg 1 year Forecast
$6.2M-19.16%
Avg 2 year Forecast
$7.5M-2.97%
BIAF's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

BIAF revenue growth forecast

How is BIAF forecast to perform vs Diagnostics & Research companies and vs the US market?

Company
-19.16%
Industry
3.54%
Market
1,351.2%
BIAF's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
BIAF's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

BIAF vs Diagnostic & Research Stocks

TickerPricePrice TargetUp/downsideConsensus
BIAF$2.45N/AN/A
NDRA$5.25$38.00+623.81%Buy
ISPC$0.78N/AN/A
BNBX$3.45N/AN/A
XWEL$0.88N/AN/A

Bioaffinity Technologies Stock Forecast FAQ

What is BIAF's earnings growth forecast for 2025-2026?

(NASDAQ: BIAF) Bioaffinity Technologies's forecast annual earnings growth rate of N/A is not forecast to beat the US Diagnostics & Research industry's average forecast earnings growth rate of 37.01%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 2,843.31%.

Bioaffinity Technologies's earnings in 2025 is -$11,688,941.On average, 3 Wall Street analysts forecast BIAF's earnings for 2025 to be -$13,938,089, with the lowest BIAF earnings forecast at -$13,391,498, and the highest BIAF earnings forecast at -$14,348,033.

In 2026, BIAF is forecast to generate -$7,840,175 in earnings, with the lowest earnings forecast at -$7,532,717 and the highest earnings forecast at -$8,070,769.

If you're new to stock investing, here's how to buy Bioaffinity Technologies stock.

What is BIAF's revenue growth forecast for 2025-2026?

(NASDAQ: BIAF) Bioaffinity Technologies's forecast annual revenue growth rate of -19.16% is not forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 3.54%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 1,351.2%.

Bioaffinity Technologies's revenue in 2025 is $7,681,059.On average, 3 Wall Street analysts forecast BIAF's revenue for 2025 to be $5,891,993, with the lowest BIAF revenue forecast at $5,660,451, and the highest BIAF revenue forecast at $6,064,701.

In 2026, BIAF is forecast to generate $7,072,480 in revenue, with the lowest revenue forecast at $6,795,388 and the highest revenue forecast at $7,280,298.

What is BIAF's forecast return on assets (ROA) for 2025-2026?

(NASDAQ: BIAF) forecast ROA is -165.02%, which is lower than the forecast US Diagnostics & Research industry average of 10.25%.

What is BIAF's Earnings Per Share (EPS) forecast for 2025-2026?

(NASDAQ: BIAF) Bioaffinity Technologies's current Earnings Per Share (EPS) is -$21.00. On average, analysts forecast that BIAF's EPS will be -$14.69 for 2025, with the lowest EPS forecast at -$14.11, and the highest EPS forecast at -$15.12. In 2026, BIAF's EPS is forecast to hit -$8.26 (min: -$7.94, max: -$8.51).

What is BIAF's forecast return on equity (ROE) for 2025-2026?

(NASDAQ: BIAF) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.